These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 24037760)

  • 1. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
    Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
    Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Massively parallel sequencing of ataxia genes after array-based enrichment.
    Hoischen A; Gilissen C; Arts P; Wieskamp N; van der Vliet W; Vermeer S; Steehouwer M; de Vries P; Meijer R; Seiqueros J; Knoers NV; Buckley MF; Scheffer H; Veltman JA
    Hum Mutat; 2010 Apr; 31(4):494-9. PubMed ID: 20151403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.
    Won HH; Scott SN; Brannon AR; Shah RH; Berger MF
    J Vis Exp; 2013 Oct; (80):e50710. PubMed ID: 24192750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
    Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
    Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
    Lorkowski SW; Dermawan JK; Rubin BP
    Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.
    Lumachi F; Marino F; Varotto S; Basso U
    Ann N Y Acad Sci; 2009 Sep; 1175():89-92. PubMed ID: 19796081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
    Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
    J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.
    Kim TM; Jung SH; Baek IP; Lee SH; Choi YJ; Lee JY; Chung YJ; Lee SH
    J Pathol; 2014 Aug; 233(4):425-35. PubMed ID: 24870262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient identification of miRNAs for classification of tumor origin.
    Søkilde R; Vincent M; Møller AK; Hansen A; Høiby PE; Blondal T; Nielsen BS; Daugaard G; Møller S; Litman T
    J Mol Diagn; 2014 Jan; 16(1):106-15. PubMed ID: 24211363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characterisation of molecular targets in carcinoma of unknown primary.
    Clynick B; Dessauvagie B; Sterrett G; Harvey NT; Allcock RJN; Saunders C; Erber W; Meehan K
    J Transl Med; 2018 Jul; 16(1):185. PubMed ID: 29973234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Massively parallel DNA sequencing from routinely processed cytological smears.
    Piqueret-Stephan L; Marcaillou C; Reyes C; Honoré A; Letexier M; Gentien D; Droin N; Lacroix L; Scoazec JY; Vielh P
    Cancer Cytopathol; 2016 Apr; 124(4):241-53. PubMed ID: 26505273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep sequencing in cancer research.
    Yoshida K; Sanada M; Ogawa S
    Jpn J Clin Oncol; 2013 Feb; 43(2):110-5. PubMed ID: 23225907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test.
    Monzon FA; Medeiros F; Lyons-Weiler M; Henner WD
    Diagn Pathol; 2010 Jan; 5():3. PubMed ID: 20205775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.
    Varadhachary GR; Spector Y; Abbruzzese JL; Rosenwald S; Wang H; Aharonov R; Carlson HR; Cohen D; Karanth S; Macinskas J; Lenzi R; Chajut A; Edmonston TB; Raber MN
    Clin Cancer Res; 2011 Jun; 17(12):4063-70. PubMed ID: 21531815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.